However, the sensitivity for NRAS/BRAF was only 82.5% since the highest number of false negatives were reported for sample type B. For the EGFR and MSI assays, all samples selected in this study belong to lung and CRC entities, respectively, so a comparison between sample types could not be achieved for them. This evidence concerns the gene EGFR and colorectal carcinoma.